CohBar advances early-stage study of CB4211 in NASH and obesity patients

Print Friendly, PDF & Email

CLINICAL TRIAL: Dosing is underway in the second part of CohBar’s ( CWBR +1.4%) Phase 1a/1b trial evaluating lead candidate CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity. The study is designed to assess the potential effects of CB4211 on liver fat, body weight, and various biomarkers relevant […]